Assessing the impact of AGS-004, a dendritic cell-based immunotherapy, and vorinostat on persistent HIV-1 Infection

Immunogenicity of AGS-004 Dendritic Cell Therapy in Patients Treated During Acute HIV Infection

(2018) Cynthia L. Gay et al.   AIDS RESEARCH AND HUMAN RETROVIRUSES

Interleukin-15-Stimulated Natural Killer Cells Clear HIV-1-Infected Cells following Latency Reversal Ex Vivo

(2018) Carolina Garrido et al.   JOURNAL OF VIROLOGY

Expanded cellular clones carrying replication-competent HIV-1 persist, wax, and wane

(2018) Zheng Wang et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Host genetics contributes to the effectiveness of dendritic cell-based HIV immunotherapy

(2018) Edione C. Reis et al.   Human Vaccines & Immunotherapeutics

In vivo Administration of histone deacetylase inhibitors does not impair natural killer cell function in HIV+ individuals

(2018) Carolina Garrido et al.   AIDS

Interval dosing with the HDAC inhibitor vorinostat effectively reverses HIV latency

(2017) Nancie M. Archin et al.   JOURNAL OF CLINICAL INVESTIGATION

SLDAssay : A software package and web tool for analyzing limiting dilution assays

(2017) Ilana M Trumble et al.   JOURNAL OF IMMUNOLOGICAL METHODS

The Molecular Basis for Human Immunodeficiency Virus Latency

(2017) Uri Mbonye et al.   Annual Review of Virology

Vorinostat Renders the Replication-Competent Latent Reservoir of Human Immunodeficiency Virus (HIV) Vulnerable to Clearance by CD8 T Cells

(2017) Julia A. Sung et al.   EBioMedicine

HIV-1 transcriptional activity during frequent longitudinal sampling in aviremic patients on antiretroviral therapy

(2016) Steffen Leth et al.   AIDS

Immunization of HIV-1-Infected Persons With Autologous Dendritic Cells Transfected With mRNA Encoding HIV-1 Gag and Nef

(2016) Rajesh T. Gandhi et al.   JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES

Dendritic Cell Immunotherapy for HIV-1 Infection Using Autologous HIV-1 RNA

(2016) Jeffrey M. Jacobson et al.   JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES

The differential short- and long-term effects of HIV-1 latency-reversing agents on T cell function

(2016) G. Clutton et al.   Scientific Reports

Dose-responsive gene expression in suberoylanilide hydroxamic acid-treated resting CD4+ T cells

(2015) Brian Reardon et al.   AIDS

Dual-Affinity Re-Targeting proteins direct T cell–mediated cytolysis of latently HIV-infected cells

(2015) Julia A.M. Sung et al.   JOURNAL OF CLINICAL INVESTIGATION

Therapeutic Vaccination With Dendritic Cells Loaded With Autologous HIV Type 1–Infected Apoptotic Cells

(2015) Bernard J. C. Macatangay et al.   JOURNAL OF INFECTIOUS DISEASES

Precise Quantitation of the Latent HIV-1 Reservoir: Implications for Eradication Strategies

(2015) Amanda M. Crooks et al.   JOURNAL OF INFECTIOUS DISEASES

The Depsipeptide Romidepsin Reverses HIV-1 Latency In Vivo

(2015) Ole S. Søgaard et al.   PLoS Pathogens

Survival with AGS-003, an autologous dendritic cell–based immunotherapy, in combination with sunitinib in unfavorable risk patients with advanced renal cell carcinoma (RCC): Phase 2 study results

(2015) Asim Amin et al.   Journal for ImmunoTherapy of Cancer

Dendritic cell-based therapeutic vaccine elicits polyfunctional HIV-specific T-cell immunity associated with control of viral load

(2014) Yves Lévy et al.   EUROPEAN JOURNAL OF IMMUNOLOGY

Eradicating HIV-1 infection: seeking to clear a persistent pathogen

(2014) Nancie M. Archin et al.   NATURE REVIEWS MICROBIOLOGY

The Immunologic Effects of Mesalamine in Treated HIV-Infected Individuals with Incomplete CD4+ T Cell Recovery: A Randomized Crossover Trial

(2014) Ma Somsouk et al.   PLoS One

Exome analysis of HIV patients submitted to dendritic cells therapeutic vaccine reveals an association of CNOT1 gene with response to the treatment

(2014) Ronald Moura et al.   Journal of the International AIDS Society

Activation of HIV Transcription with Short-Course Vorinostat in HIV-Infected Patients on Suppressive Antiretroviral Therapy

(2014) Julian H. Elliott et al.   PLoS Pathogens

Panobinostat, a histone deacetylase inhibitor, for latent-virus reactivation in HIV-infected patients on suppressive antiretroviral therapy: a phase 1/2, single group, clinical trial

(2014) Thomas A Rasmussen et al.   Lancet HIV

Replication-Competent Noninduced Proviruses in the Latent Reservoir Increase Barrier to HIV-1 Cure

(2013) Ya-Chi Ho et al.   CELL

Impact of Autologous Dendritic Cell–Based Immunotherapy (AGS-004) on B- and T-Cell Subset Changes and Immune Activation in HIV-Infected Patients Receiving Antiretroviral Therapy

(2013) Mohammad-Ali Jenabian et al.   JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES

Suberoylanilide hydroxamic acid induces limited changes in the transcriptome of primary CD4+ T cells

(2012) Nadejda Beliakova-Bethell et al.   AIDS

Administration of vorinostat disrupts HIV-1 latency in patients on antiretroviral therapy

(2012) N. M. Archin et al.   NATURE

Valproic acid without intensified antiviral therapy has limited impact on persistent HIV infection of resting CD4+ T cells

(2008) Nancy M Archin et al.   AIDS

A universal real-time PCR assay for the quantification of group-M HIV-1 proviral load

(2008) Mauro S Malnati et al.   Nature Protocols